Lipidem (Omega-3-Acid Triglycerides, Soya-Bean Oil Refined, Triglycerides, Medium Chain)

The omega‑3‑acid triglycerides in Lipidem are hydrolyzed by plasma lipases into free fatty acids and glycerol. These are incorporated into cell membranes and oxidized for energy, delivering essential fatty acids and caloric support required for patients on parenteral nutrition.

The dose of Lipidem is individualized by the prescribing clinician based on the patient’s caloric requirements, lipid tolerance, and clinical condition. Dosage calculations consider factors such as body weight, metabolic needs, and laboratory monitoring.

Safety data for Lipidem in pregnancy and lactation are limited. It should only be used if the potential benefit to the mother outweighs any possible risk to the fetus or infant, and the decision must be made by the treating physician.

To order Lipidem, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and import documentation.

Lipidem contains omega‑3‑acid triglycerides derived from refined soybean oil, offering a balanced profile of essential fatty acids. Compared with emulsions based solely on soybean or safflower oil, Lipidem provides higher omega‑3 content, which may better support anti‑inflammatory effects and membrane fluidity, though clinical choice depends on patient-specific factors and institutional protocols.

Lipidem must be stored at 2‑8 °C in a refrigerator, protected from light. Do not freeze or shake the container. Before administration, allow the product to reach room temperature if required by the infusion protocol, and inspect for any signs of contamination or phase separation.

Lipidem is administered intravenously as an infusion, typically added to a total parenteral nutrition bag or given as a separate lipid infusion. The infusion rate is set by the clinician based on the prescribed lipid dose and the patient’s tolerance, with continuous monitoring for adverse reactions.

The most serious risks include fat overload syndrome, severe hypertriglyceridemia, pulmonary embolism, and anaphylactic reactions. Patients should be closely monitored for signs of respiratory distress, rapid rise in triglyceride levels, and any allergic manifestations during and after infusion.

Lipidem should be avoided in patients with known hypersensitivity to soybean oil, egg phospholipids, or any component of the emulsion. It is also contraindicated in individuals with severe hyperlipidemia, uncontrolled sepsis, or those receiving multiple lipid sources that could cause fat overload.